Over 200 years of experience
in the pharmaceutical industry
FDF, API, CMO, CDMOPharmaceutical development and manufacturing
-
Contract manufacturing
Learn moreWe specialise in the production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). Our production lines for highly potent medicines (OEB 5) are among the most advanced in Central and Eastern Europe. We operate in full compliance with EU cGMP, FDA and EAEU standards.
-
Laboratory services
Learn moreWe offer comprehensive preformulation and analytical support. In 2025, we launched a state-of-the-art laboratory for highly potent parenteral products (OEB 5). Our team performs over 4,000 tests annually.
Over 50 products in 130 forms and doses
We manufacture prescription (Rx) medicines – antibiotics, human insulins, CNS and dermatological products – as well as over-the-counter (OTC) medicines, dietary supplements and dermocosmetics. Every year, we deliver over 25 million packages to hospitals, pharmacies and healthcare institutions, supporting the health and well-being of patients worldwide.
View portfolioWe manufacture in Poland
– for a safer tomorrow
We are the oldest pharmaceutical company in Poland and one of the oldest in Europe. Since 1823, we have been building the foundations of Polish pharmacy by introducing groundbreaking solutions. We were the first in the country to start producing penicillin, insulin and antibiotics, setting new standards in treatment. Today, we produce 10% of the medicines classified as critical by the European Union, helping to secure treatment access for millions of patients.
News
-
23.10.2025AnnouncementsCenter for Development and Production of Highly Potent Drugs
TZF Polfa, a Polish pharmaceutical manufacturer, proudly presents its latest venture in Warsaw – the Center for Development and Production of Highly Potent Drugs, one of the most advanced injectable drug manufacturing facilities in Europe. This technologically advanced plant fully meets the growing global demand for injectable medicines in various pharmaceutical forms. The facility covers […]Read more -
30.04.2026AnnouncementsAppointment of the President of Management Board of TZF Polfa S.A.
Following a formal selection process, the Supervisory Board has appointed Małgorzata Pajączek as President of the Management Board (CEO) of TZF Polfa, bringing to the company her extensive expertise in medicines development, manufacturing, and building national medicines security. Małgorzata Pajączek, MD PhD is an experienced leader in the pharmaceutical and biotechnology sectors, specialising in biologics, […]Read more -
16.04.2026Announcements
Appointment of the new Management Board of TZF Polfa S.A.
As a result of the conducted proceedings, the Supervisory Board of TZF Polfa S.A. has appointed Katarzyna Piotrowska-Radziewicz and Ewelina Kabała to the Company’s Management Board, whose 11th term of office began on April 14, 2026. Katarzyna Piotrowska-Radziewicz is an expert in pharmaceutical policy and pharmaceutical law, with many years of experience in public administration. […]Read more -
10.04.2026Tenders
Request for quotation Z3/5438/1 MRA Colistimethate Sodium – vials 20H, hydrolytic class I
In connection with the implementation of the project 2022/ABM/04/00016 – Development and development of a new pharmaceutical form of a medicinal product based on an approved active substance, containing the antibiotic colistimethate sodium used in the treatment of severe infections caused by gram-negative bacteria, Tarchomińskie Zakłady Farmaceutyczne POLFA S.A. invites you to submit offers for the subject of the […]Read more -
06.03.2026Tenders
Request fot quotation – RFQ Z2/5438/1 – Study monitoring – Empagliflozin
In connection with the implementation of the project 2022/ABM/04/00014-00 – „Opracowanie i rozwój produktu leczniczego z substancją czynną EMPAGLIFLOZYNĄ – leku generycznego na cukrzycę typu 2” (”Design and development of a medicinal product with the active substance EMPAGLIFLOZIN – a generic drug for type 2 diabetes”), Tarchominskie Zakłady Farmaceutyczne POLFA S.A. invites you to submit […]Read more -
05.03.2026Announcements
Selection procedure for the position of President of the Management Board
The Supervisory Board of Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., with its registered office in Warsaw, hereby announces a selection procedure for the position of President of the Management Board. Written applications should be sent by post to the Company’s address (Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., ul. A. Fleminga 2, 03-176 Warsaw) or delivered in person […]Read more -
05.03.2026Announcements
Selection procedure for the position of First Member of the Management Board
The Supervisory Board of Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., with its registered office in Warsaw, hereby announces a selection procedure for the position of First Member of the Management Board. Written applications should be sent by post or delivered in person to the Company Authorities Support Department (ul. A. Fleminga 2, 03-176 Warsaw) by March […]Read more -
05.03.2026Announcements
Selection procedure for the position of Second Member of the Management Board
The Supervisory Board of Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., with its registered office in Warsaw, hereby announces a selection procedure for the position of Second Member of the Management Board. Written applications should be sent by post to the Company’s address (Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., ul. A. Fleminga 2, 03-176 Warsaw) or delivered in […]Read more
